Till today plasmid DNA based vaccines have been proven safe but poorly immunogenic in human subjects. Genetic Immunity developed several technologies
to improve the immunogenicity of DNA-encoded antigens by delivering them to Dendritic Cells. The first application of these technologies is DermaVir Patch,
which is presently in Phase II clinical trials in Germany and Italy for the treatment of HIV/AIDS.
Genetic Immunity's immune amplification platform technology is used to develop Therapeutic Vaccines comprised of three principal technologies, ANTIGENeering, Nanomedicine
and DermaPrep, designed to work together to treat and/or control chronic diseases.
DermaVir Patch - Genetic Immunity's lead therapeutic vaccine product candidate for the treatment of HIV - is based on the combination of these three tehnologies:
ANTIGENeering technology to design plasmid DNA encoding most of the disease specific antigens (e.g. HIV, HPV, Derp1) to induce the broadest immune response.
Nanomedicine technology for the formulation of biologics to intelligent virus-like nanoparticles required for effective
uptake and antigen presentation in "professional antigen-presenting cells". In human clinical trials we have demonstrated that plasmid DNA formulated into Nanomedicine is effectively
expressed in dendritic cells.
DermaPrep technology is the first dendritic cell targeting topical vaccine delivery system. We have shown that
topical administration of liquid Nanomedicine formulations using DermaPrep results in antigen expression in the lymph node dendritic cells.
Antigen expression and presentation by dendritic cells in the lymph nodes results in amplification of antigen-specific memory T cells.
Potent initiation of de novo HIV-specific T cell response was demonstrated in mice, macaques and human subjects in several preclinical and
clinical trials.
